详细记录  
题名:Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy.
作者:MEIER JJ; PENNARTZ C; SCHENKER N; MENGE BA; SCHMIDT WE; HEISE T; KAPITZA C; VELDHUIS JD;
来源:Diabetes Obes Metab. 2013 Mar;15(3):258-63. doi: 10.1111/dom.12022. [ IF= 0.00 ] ]
URL :10.1111/dom.12022
日期:20130330
摘要:AIM: Postprandial insulin pulsatility is impaired in patients with type 2
diabetes, but the effects of exogenous insulin therapy on pulsatile insulin
secretion are not known. We addressed, whether pulsatile insulin secretion is
related to glycaemic control, whether basal insulin supplementation increases
postprandial insulin secretion, and if so, is this accomplished by a specific
improvement in pulsatile insulin secretion? METHODS: Fourteen patients with type
2 diabetes underwent a mixed meal test before and after an 8-week treatment
period with insulin glargine. Glucose, insulin and C-peptide levels were
measured, and insulin pulsatility was determined by deconvolution analysis.
RESULTS: Insulin treatment lowered fasting glycaemia from 179.6 +/- 7.5 mg/dl to
117.6 +/- 6.5 mg/dl (p < 0.001). Postprandial insulin and C-peptide levels
increased significantly after the treatment period (p < 0.0001). The total
calculated insulin secretion rate increased with insulin treatment (p = 0.0039),
with non-significant increases in both pulsatile and non-pulsatile insulin
secretion. Insulin pulse frequency was unchanged by the intervention. There was
an inverse relationship between fasting and postprandial glycaemia and insulin
pulse mass (r(2) = 0.51 and 0.56, respectively), whereas non-pulsatile insulin
secretion was unrelated to either fasting or postprandial glucose concentrations
(r(2) = 0.0073 and 0.031). CONCLUSIONS: Hyperglycaemia in type 2 diabetes is
associated with a reduction in postprandial insulin secretion, specifically
through a reduction in insulin pulsatility. Reducing chronic hyperglycaemia by
basal insulin therapy enhances endogenous beta-cell function in the postprandial
state. These data support the use of basal insulin regimens in the
pharmacotherapy of overtly hyperglycaemic patients with type 2 diabetes.

================  评  论  部  分=================

重要性:
分类:(参照 Faculty of 1000 的分类体系)


评语:

评论密码:   返回前页  [全部]